Vanderbilt University

Vanderbilt researchers are deploying artificial intelligence to automate interpretation of ECGs, medical images, and pathology slides, while advancing MRI and spatial omics techniques for earlier cancer and neurological detection. They are also pioneering wearable electrochemical biosensors, chip-free physiological monitors, and liquid biopsy assays for continuous, noninvasive disease monitoring. These innovations address critical gaps in rapid diagnosis and open commercial avenues in precision oncology, point-of-care testing, and clinical decision-support software.

Vanderbilt researchers are developing AI-driven imaging solutions that automate lesion segmentation and harmonize multi-site MRI and CT data to standardize diagnostics for neurodegeneration and cancer. Their portfolio includes low-dose CT lung screening analytics, augmented reality surgical navigation, and digital pathology platforms that address industry needs for reproducible biomarkers and precision intervention. These advances open clear commercial pathways in radiology AI, clinical trial imaging, and next-generation surgical visualization.

Vanderbilt's Medical Engineering and Discovery (MED) Lab and the Vanderbilt Institute for Surgery and Engineering develop needle-diameter continuum and steerable surgical robots for procedures across neurosurgery, urology, otolaryngology, and lung intervention—including tentacle-like arms that remove skull-base tumors through the nose and parallel robots that make cochlear-implant surgery less invasive. The lab collaborates with industry partners including Intuitive Surgical and MathWorks, and its faculty co-founded EndoTheia, whose flexible-endoscopy device holds FDA Breakthrough Device designation. This expertise in image-guided, minimally invasive systems offers surgical-device and robotics companies a proven pipeline from mechanism design toward FDA-cleared product.

Vanderbilt runs one of the country's leading antibody-discovery engines through the Vanderbilt Vaccine Center and Center for Antibody Therapeutics, rapidly isolating human monoclonal antibodies against SARS-CoV-2, Ebola, RSV, dengue, and orthopoxviruses. The program produced Evusheld, the long-acting COVID-19 antibody combination exclusively licensed to AstraZeneca under FDA emergency use authorization, licensed poxvirus antibodies to SIGA Technologies, and spun out IDBiologics to advance further therapeutics. For pharmaceutical and biotech partners, this offers a validated, FDA-proven pipeline from antibody discovery to licensed product in pandemic preparedness and infectious-disease therapeutics.

Vanderbilt pioneered large-scale precision medicine through BioVU, one of the world's largest biobanks (350,000+ DNA samples linked to de-identified electronic health records), and the PREDICT program that embeds pharmacogenomic guidance directly into clinical care. Its commercial arm, Nashville Biosciences, partners with Illumina and pharmaceutical companies to sequence and analyze these cohorts for drug-target discovery, while leadership roles in the NIH All of Us, eMERGE, and IGNITE networks extend the platform nationally. Pharma and diagnostics partners gain structured access to genotype-phenotype data at scale and a proven model for translating genomic associations into individualized prescribing.

Vanderbilt researchers are translating spatial transcriptomics, circulating tumor DNA, and AI-driven risk models into precision oncology tools that predict immunotherapy and chemotherapy response across breast, lung, and pancreatic cancers. They are engineering next-generation therapeutics—including STING-activating nanobody conjugates, macrophage-reprogramming cryogels, and pan-KRAS inhibitors—to dismantle solid tumor defenses and overcome drug resistance. By fusing novel diagnostics with targeted therapies, the work creates commercial opportunities in personalized cancer medicine while addressing treatment disparities and efficacy gaps.

Vanderbilt researchers engineer next-generation drug delivery platforms—including lipid-siRNA conjugates for CNS gene silencing and STING-activating nanoparticles for cancer immunotherapy—to overcome biological barriers and sharpen therapeutic precision. They harness AI-driven screening and computational modeling to rapidly identify clinically viable small molecules, from kinase inhibitors to ion-channel correctors. These converging pipelines target urgent unmet needs in oncology, genetic disease, and neurology while advancing scalable candidates toward commercialization and clinical partnership.

Vanderbilt researchers are translating AI-driven brain charts, plasma biomarkers, and digital phenotyping into early diagnostics for Alzheimer’s, frontotemporal dementia, and traumatic brain injury. They are also advancing closed-loop neuromodulation for epilepsy, next-generation stroke thrombectomy devices, and CSF-delivered therapeutics that bypass the blood-brain barrier. Together, these platforms form a commercially oriented pipeline for precision neurology.